Pharmaceuticals Companies - Business Exchange Most Active Articles 2009-11-26T06:34:57.385-05:00 Business Exchange Business_Exchange@businessweek.com urn:com:businessweek:bx:topic:most-active:pharmaceuticals-companies Henri TCHEN htchen963 Novartis' Sullivan on cross-border dealmaking (Dealscape urn:com:businessweek:bx:article:10474804778506115800-9026ed673bfda0f0ca1675c9418de481 2009-11-18T15:31:00.480-05:00 Marvelle Sullivan, the head of corporate legal M&A at Novartis AG (NYSE:NVS), spoke at The Deal Economy 2010 conference on Wednesday in New York City. In this video, she explains several challenges confronting companies working on cross-border... Marvelle Sullivan, the head of corporate legal M&A at Novartis AG (NYSE:NVS), spoke at The Deal Economy 2010 conference on Wednesday in New York City. In this video, she explains several challenges confronting companies working on cross-border... thedeal.com http://www.thedeal.com/dealscape/2009/11/novartis_sullivan_on.php Brennen Wysong bwysong598 2 2 0 0 Pfizer slashing R&D footprint by 35% urn:com:businessweek:bx:article:14925009496694729302-8d042eea6f09e0af5e7ccff72a33714b 2009-11-10T14:44:25.358-05:00 Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth. Pfizer Inc. (NYSE:PFE) employees concerned about their jobs may have a better idea of where they stand. The pharmaceutical giant on Monday announced plans to consolidate 20 R&D centers into five central hubs as part of its integration of Wyeth. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/11/pfizer_slashing_rd_footprint_b.php Brennen Wysong bwysong598 2 2 0 0 Onyx Pharma dealmakers build M&A culture urn:com:businessweek:bx:article:7905358182006758655-bed411c8b72f56cb36bb890c8b7c8969 2009-11-02T15:51:32.040-05:00 When Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) bought Proteolix Inc. on Oct. 12, (The Deal Pipeline subscription required) it was the first-ever acquisition for the 17-year-old Emeryville, Calif. firm. And in an industry underpinned by licensing deals, Onyx has only signed two, both coming in 2008. Rather than look outside for growth, Onyx has been developing Nexavar, a drug approved in more than 100 countries to treat liver and kidney cancers. When Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) bought Proteolix Inc. on Oct. 12, (The Deal Pipeline subscription required) it was the first-ever acquisition for the 17-year-old Emeryville, Calif. firm. And in an industry underpinned by licensing deals, Onyx has only signed two, both coming in 2008. Rather than look outside for growth, Onyx has been developing Nexavar, a drug approved in more than 100 countries to treat liver and kidney cancers. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/11/onyx_pharma_dealmakers_on_buil.php Brennen Wysong bwysong598 5 5 0 0 Pharmaceutical Industry Set to Emerge as winners in the Healthcare Reform urn:com:businessweek:bx:article:15784453230940966286-8f76fbe7e8981f18a9d5b85da605b41b 2009-10-20T04:40:00.909-04:00 Once a powerful profit-machine, big pharma is stumbling ,the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to “weather the Healthcare Reform”. Once a powerful profit-machine, big pharma is stumbling ,the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to “weather the Healthcare Reform”. current.com http://current.com/items/91228334_pharmaceutical-industry-set-to-emerge-as-winners-in-the-healthcare-reform.htm Emma Naylor enaylor109 10 10 0 0 Why These Ten Companies Should Let Go of Their CEOs in 2009 urn:com:businessweek:bx:article:4947136885381980922-2592b8be466a2e0b13895a87a1f2bccb 2008-12-06T13:17:54.339-05:00 Each year we come out with a list of companies who should get rid of their CEOs or which should make some strategic changes inside the company that revolve around the CEO and management. Each year we come out with a list of companies who should get rid of their CEOs or which should make some strategic changes inside the company that revolve around the CEO and management. 247wallst.com http://www.247wallst.com/2008/12/10-ceos-to-go-8.html Ashley Allen aallen237 153 153 0 0 Johnson & Johnson earnings preview urn:com:businessweek:bx:article:16936065082414819425-43e6c5aa2eb77870ae3ec956ddf4f738 2009-10-12T13:24:47.410-04:00 Johnson & Johnson (NYSE:JNJ), the world's biggest healthcare company that's been squeezed by generic competition, reports third-quarter earnings Tuesday morning. Alex Gorsky, worldwide chairman of medical devices and diagnostics; Dominic Caruso, vice president of finance and CFO; and Louise Mehrotra, VP of investor relations, will speak about the report via Webcast at 8:30 a.m. ET. Johnson & Johnson (NYSE:JNJ), the world's biggest healthcare company that's been squeezed by generic competition, reports third-quarter earnings Tuesday morning. Alex Gorsky, worldwide chairman of medical devices and diagnostics; Dominic Caruso, vice president of finance and CFO; and Louise Mehrotra, VP of investor relations, will speak about the report via Webcast at 8:30 a.m. ET. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/10/johnson_johnson_earnings_previ.php Brennen Wysong bwysong598 8 8 0 0 Pharmaceutical Company Outlook to 2013 urn:com:businessweek:bx:article:2298229308034517507-0af4f4834d056aede85f9618adcad1a8 2009-02-18T06:55:00.000-05:00 molecule type analysis 20 PharmaVitae Universe M&A analysis 23 PharmaVitae Universe operating performance analysis 25 CHAPTER 2 THE BIG PHARMA OUTLOOK TO 2013 30 Key findings 30 Overview of Big Pharma to 2013 31 Big Pharma Rx pharma sales molecule type analysis 20 PharmaVitae Universe M&A analysis 23 PharmaVitae Universe operating performance analysis 25 CHAPTER 2 THE BIG PHARMA OUTLOOK TO 2013 30 Key findings 30 Overview of Big Pharma to 2013 31 Big Pharma Rx pharma sales Reuters http://c.moreover.com/click/here.pl?r1826713827&f=9791 86 84 1 1 Abbott Labs earnigns preview urn:com:businessweek:bx:article:17863582824126438015-f5e754c167a561d0180e714f3087d326 2009-10-12T15:52:14.212-04:00 Since winning The Deal's Most Admired Corporate Dealmaker award in the healthcare category in 2008, Abbott Laboratories (NYSE:ABT) has continued to aggressively pursue acquisitions. The company has announced five deals so far this year. Since winning The Deal's Most Admired Corporate Dealmaker award in the healthcare category in 2008, Abbott Laboratories (NYSE:ABT) has continued to aggressively pursue acquisitions. The company has announced five deals so far this year. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/10/earnings_preview_abbott_labs.php Brennen Wysong bwysong598 5 5 0 0 Revenue Optimization: Coming Soon to a Big Drug Company Near You urn:com:businessweek:bx:article:1980691225460196736-375b238aef47cc327e415ae207e3b203 2009-09-14T16:54:30.972-04:00 Major trends with potentially far-reaching consequences for Big Pharma are underway that will likely influence drug makers’ lax pricing approaches for their brand-name drugs – in particular when those drugs reach the end of their exclusivity protection period and go off patent. Major trends with potentially far-reaching consequences for Big Pharma are underway that will likely influence drug makers’ lax pricing approaches for their brand-name drugs – in particular when those drugs reach the end of their exclusivity protection period and go off patent. blog.sentrana.com http://blog.sentrana.com/2009/09/11/revenue-optimization-coming-soon-to-a-big-drug-company-near-you/ Joe Smiley jsmiley701 4 3 0 1 Drug Mergers: Killers for Research urn:com:businessweek:bx:article:2360515815255126107-a0947cef48fb72fe5097aa4cc8f69652 2009-03-09T23:26:16.844-04:00 Merck's decision to acquire Schering-Plough (SGP) for $41 billion will improve its bottom line over the next two to three years, as the merged company cuts at least 16,000 staffers and streamlines its operating costs. Further out, however, Merck... Merck's decision to acquire Schering-Plough (SGP) for $41 billion will improve its bottom line over the next two to three years, as the merged company cuts at least 16,000 staffers and streamlines its operating costs. Further out, however, Merck... BusinessWeek http://www.businessweek.com/technology/content/mar2009/tc2009039_020072.htm?chan=top+news_top+news+index+-+temp_top+story John A. Byrne jbyrne076 49 47 2 0 Doozy of a Day One for Pfizer-Wyeth R&D urn:com:businessweek:bx:article:17157515297585969303-72464f7b2c401aecc823de2407e21169 2009-10-16T14:53:26.107-04:00 On Wednesday, Pfizer Inc. (NYSE:PFE) received approval from the FTC for its $68 billion acquisition of Wyeth. Friday is Day One for the combined companies. The mood at the two giant organizations no doubt varies by function and location. But a juxtaposition of two facts in a Bloomberg report suggests the swirl of emotions researchers at the two companies may be feeling. On Wednesday, Pfizer Inc. (NYSE:PFE) received approval from the FTC for its $68 billion acquisition of Wyeth. Friday is Day One for the combined companies. The mood at the two giant organizations no doubt varies by function and location. But a juxtaposition of two facts in a Bloomberg report suggests the swirl of emotions researchers at the two companies may be feeling. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/10/pfizer-wyeth_day_one.php Brennen Wysong bwysong598 0 0 0 0 AcelRx hires dealmaker to hunt partners urn:com:businessweek:bx:article:8592727142045250793-aafe5bf1eda0199f065075e223e9486f 2009-10-15T16:19:59.889-04:00 AcelRx Pharmaceuticals has a handful of mid- and late-state clinical products in development, which would make this a good time to seek strategic partners. To make it happen, the biotechnology firm has hired Nigel Ray as vice president of business development. AcelRx Pharmaceuticals has a handful of mid- and late-state clinical products in development, which would make this a good time to seek strategic partners. To make it happen, the biotechnology firm has hired Nigel Ray as vice president of business development. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/10/acelrx_hires_dealmaker_to_hunt.php Brennen Wysong bwysong598 0 0 0 0 Onyx Pharma acquisition drives trend urn:com:businessweek:bx:article:9558162406967609533-ec5933fc7c5abcca166bb5cb98c68087 2009-10-12T13:26:15.380-04:00 Oncology deals keep coming. A week and a half after Sanofi-Aventis SA (NYSE:SNY) acquired the rights to sell an experimental cancer treatment developed by Merrimack Pharmaceuticals Inc. for up to $530 million, Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) said it's buying cancer drug developer Proteolix Inc. in a deal that could be worth up to $851 million. Oncology deals keep coming. A week and a half after Sanofi-Aventis SA (NYSE:SNY) acquired the rights to sell an experimental cancer treatment developed by Merrimack Pharmaceuticals Inc. for up to $530 million, Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) said it's buying cancer drug developer Proteolix Inc. in a deal that could be worth up to $851 million. thedeal.com http://www.thedeal.com/corporatedealmaker/2009/10/onyx_pharma_acquisition_drives.php Brennen Wysong bwysong598 0 0 0 0 Vaccines are Hot urn:com:businessweek:bx:article:15597421068609565522-bac7c4b79e26517493837078551d7506 2009-10-12T03:34:55.773-04:00 The race to offer H1N1 flu vaccination is picking up pace. While global H1N1 vaccine manufacturers like Sanofi Pasteur, Novartis and MedImmune have begun shipping their products, Indian vaccine majors Serum Institute of India, Panacea Biotech and Bharat Biotech are likely to start human clinical trials by the year-end and the H1N1 vaccine will hit the market by March-April next year. The race to offer H1N1 flu vaccination is picking up pace. While global H1N1 vaccine manufacturers like Sanofi Pasteur, Novartis and MedImmune have begun shipping their products, Indian vaccine majors Serum Institute of India, Panacea Biotech and Bharat Biotech are likely to start human clinical trials by the year-end and the H1N1 vaccine will hit the market by March-April next year. financialexpress.com http://www.financialexpress.com/news/vaccines-are-hot/527770/ Bruce Einhorn beinhorn468 0 0 0 0 Flu a windfall for some drugmakers, shares jump urn:com:businessweek:bx:article:10078340605416971661-10573900e0e7e31e208a1678ddb060b4 2009-04-27T12:37:43.577-04:00 Threat of a pandemic triggered by a new swine flu strain will provide a windfall for some makers of drugs and vaccines. Threat of a pandemic triggered by a new swine flu strain will provide a windfall for some makers of drugs and vaccines. Reuters http://www.reuters.com/article/wtUSInvestingNews/idUSTRE53Q11K20090427 Shirley Brady sbrady224 26 26 0 0 ‘No Frills Drugs’ push Pharmaceutical companies to look for a cure urn:com:businessweek:bx:article:17777822900560086172-022b057e85eadb9b991234b267c25bcf 2009-09-30T04:06:43.571-04:00 ‘No Frills Drugs’ push Pharmaceutical companies to look for a cure GSK, Bayer, AstraZeneca, Novartis and Mylan meet to discuss pharmaceutical futures. The pharmaceutical industry is sharing the symptoms of the economic downturn. Counterfeit drug... ‘No Frills Drugs’ push Pharmaceutical companies to look for a cure GSK, Bayer, AstraZeneca, Novartis and Mylan meet to discuss pharmaceutical futures. The pharmaceutical industry is sharing the symptoms of the economic downturn. Counterfeit drug... chemtracker.net http://www.chemtracker.net/industry_news_discussions/%E2%80%98no_frills_drugs%E2%80%99_push_pharmaceutical_companies_to_look_cure Emma Naylor enaylor109 1 1 0 0 Keep an eye on oncology deals, too urn:com:businessweek:bx:article:7302055230533414703-5d635ffca5d341013878bf9fe61ebdad 2009-09-29T15:31:16.559-04:00 We're tracking a subsector that's been hot with dealmaking -- oncology. We're tracking a subsector that's been hot with dealmaking -- oncology. Corporate Dealmaker http://www.thedeal.com/corporatedealmaker/2009/09/keep_an_eye_on_oncology_deals.php Brennen Wysong bwysong598 0 0 0 0 Pharmacies Fight Tough Battle on Generic Prices urn:com:businessweek:bx:article:8266826261869644897-9bf5b05c6e7b7807ae104a1ef60d09f4 2008-12-22T22:13:33.038-05:00 WSJ.com is available in the following editions and languages: WSJ.com is available in the following editions and languages: online.wsj.com http://online.wsj.com/article/SB122990612110525373.html#articleTabs%3Dcomments Girish Malhotra gmalhotra532 34 34 0 0 Drug companies told to stop giving doctors 'gifts' urn:com:businessweek:bx:article:5952048064097748719-acd82b0d7daa5bbb3421e24702aadf42 2009-02-01T06:30:00.000-05:00 The Royal College of Physicians is calling for an end to a 'culture' of doctors receiving freebies from pharmaceutical companies after it led an inquiry into the relationship between the profession and such firms, the BBC reported. Currently, drug The Royal College of Physicians is calling for an end to a 'culture' of doctors receiving freebies from pharmaceutical companies after it led an inquiry into the relationship between the profession and such firms, the BBC reported. Currently, drug Mail Online UK http://c.moreover.com/click/here.pl?r1799051386&f=9791 31 31 0 0 Ramius Capital Group Buys Drug Companies, Moves out of ETFs urn:com:businessweek:bx:article:4037781520931391132-8e18be004adb381326fe47f4387277a3 2009-09-19T21:20:48.102-04:00 Ramius Capital Group's most recent portfolio holdings reveal that the hedge fund manager has shifted its portfolio focus to drug manufacturers. The firm's exposure to US Equity as of June 30th was $366mm, which is down from $788mm at the end of... Ramius Capital Group's most recent portfolio holdings reveal that the hedge fund manager has shifted its portfolio focus to drug manufacturers. The firm's exposure to US Equity as of June 30th was $366mm, which is down from $788mm at the end of... hedgetracker.com http://www.hedgetracker.com/article/Ramius-Capital-Group-Buys-Drug-Companies-Moves-out-of-ETFs Todd Walker rwienke085 0 0 0 0 Venture capital firm set to reap rewards on swine flu urn:com:businessweek:bx:article:8763479928581851311-b0fbcfe485f5515e8d9f9dd94113486e 2009-04-27T12:36:37.835-04:00 The swine flu outbreak is likely to benefit Kleiner Perkins Caufield & Byers because of the firm's portfolio of eight Pandemic and Bio Defense companies -- BioCryst Pharmaceuticals and Novavax. The swine flu outbreak is likely to benefit Kleiner Perkins Caufield & Byers because of the firm's portfolio of eight Pandemic and Bio Defense companies -- BioCryst Pharmaceuticals and Novavax. Reuters http://www.reuters.com/article/wtUSInvestingNews/idAFN2425534220090424 Shirley Brady sbrady224 13 13 0 0 Pharma career portal: FindPharma job listings urn:com:businessweek:bx:article:15967600218337738514-54aa0f0635d315e1602987f0789a6762 2009-08-29T22:12:26.317-04:00 nonclinicaljobs.com http://www.nonclinicaljobs.com/2009/08/pharma-career-portal-findpharma-job.html Joseph Kim, MD, MPH jkimmdmph200 2 2 0 0 This is the new business model for pharma? urn:com:businessweek:bx:article:9949637950790092870-ba36cfb0130dd0a8b0f2fbd6c72573fe 2008-10-02T12:22:00.000-04:00 Cash starved companies are going to ... of bureaucratic big pharma processes that slow drug Cash starved companies are going to ... of bureaucratic big pharma processes that slow drug World of DTC Marketing http://www.worldofdtcmarketing.com/files/b5edd83854e70dc1cc3fe8ae8b5d281f-462.html 45 44 0 1 Lilly eyes entry into biogenerics arena urn:com:businessweek:bx:article:11431046931816665389-c3d882fef06c1df166675604111f6405 2008-12-12T11:33:12.108-05:00 Two days after Merck & Co announced a major push into generic versions of biotechnology medicines, Eli Lilly and Co have signaled similar aspirations "down the road." Two days after Merck & Co announced a major push into generic versions of biotechnology medicines, Eli Lilly and Co have signaled similar aspirations "down the road." Reuters http://www.reuters.com/article/rbssHealthcareNews/idUSN1138748320081211 Shirley Brady sbrady224 30 30 0 0 Small and flexible: the manufacturing of tomorrow urn:com:businessweek:bx:article:12904414049637402687-fd113a6d7383bb6c613462975700f455 2009-03-24T08:53:32.707-04:00 Biopharmaceutical manufacturing is likely to undergo a dramatic change over the next 20 years, with the today's facilities facing dramatic change or obsolescence. That was one of the main take-home messages from a panel discussion at the Interphex show in New York last week. Biopharmaceutical manufacturing is likely to undergo a dramatic change over the next 20 years, with the today's facilities facing dramatic change or obsolescence. That was one of the main take-home messages from a panel discussion at the Interphex show in New York last week. pharmafocus.com http://www.pharmafocus.com/cda/focusH/1,2109,21-0-0-MAR_2009-focus_news_detail-0-492622,00.html Robert Hans rhans436 16 16 0 0